A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
Other websites with additional information:
See below link for recently released study results!
Do you Qualify?
These questions require a yes answer to qualify.
Are you between the ages of age 65 and 80?
Do you have a reliable study partner who will provide written informed consent to participate and is in frequent contact with the participant (you)? **The study partner must be familiar with overall function and behavior, such as day-to-day activities and cognitive abilities.**
Do you have adequate literacy, vision, and hearing for neuropsychological testing?
These questions require a no answer to qualify.
Have you ever been diagnosed with Mild cognitive impairment or dementia, or significant other neurodegenerative disease that affects cognition?
Do you have any current serious or unstable illnesses including cardiovascular, hepatic, renal, gastroenterological, respiratory, endocrinologic, neurologic, psychiatric, immunologic, or hematologic disease and other conditions that, in the investigator’s opinion, could interfere with the analyses in this study; or has a life expectancy of approximately ≤5 years?
Do you have any history of cancer with high risk of recurrence?
Do you have a history of clinically significant multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions (including but not limited to erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, and/or exfoliative dermatitis)?
Do you have any contraindications for MRI, including claustrophobia or the presence of contraindicated metal (ferromagnetic) implants/cardiac pacemaker?
Do you have any current or previous use of prescription medications used as treatment for MCI or AD?
If you think you may be eligible for this trial, please give us a call to schedule an appointment or click button below to email a request.